Michael J. McElhaugh, Interim President & CEO at Arbutus Biopharma Corp (ABUS), sold 10,164 shares at $2.31 ($23K) on 2024-02-02, disclosed to the SEC on 2024-02-05.
Scheduled sale ($23k) by Interim President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ABUS | SELL | 2020-12-16 | $200K | — | Filing → |
| ABUS | SELL | 2020-07-27 | $100K | — | Filing → |